RT Journal Article
SR Electronic
T1 Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP e2132
OP e2137
DO 10.1212/WNL.0000000000011712
VO 96
IS 16
A1 de Havenon, Adam
A1 Delic, Alen
A1 Dehoney, Sarah
A1 Whetman, Presley
A1 Sheibani, Nazanin
A1 Callaghan, Brian
A1 Ney, John
A1 Esper, Gregory J.
A1 Magliocco, Brandon
A1 Nair, Kavita V.
YR 2021
UL http://n.neurology.org/content/96/16/e2132.abstract
AB Objective To determine whether there was an increase in payments for neurologist-prescribed drugs, we performed a retrospective analysis of prescription claims in the Medicare Part D Prescriber Public Use Files from 2013 to 2017.Methods We included claims prescribed by providers with the taxonomy “neurology” and included drugs present in all 5 years. Drugs were designated in 2013 as generic (GEN), brand name only (BNO), and brand name prescribed even though a generic equivalent is available (BNGE). To observe payment trends, the percentage change in the per claim payment was compared between drug classes.Results We included 520 drugs, of which 322 were GEN, 61 were BNO, and 137 were BNGE, representing 90,716,536 claims and generating payments of $26,654,750,720. While the number of claims from 2013 to 2017 increased only 7.6%, the total payment increased 50.4%. Adjusted for inflation, claim payments for GEN drug increased 0.6%, compared to significant increases in BNO and BNGE drugs of 42.4% and 45.0% (ptrend < 0.001). The percentage of overall GEN claims increased from 81.9% to 88.0%, BNO increased from 4.9% to 6.2%, and BNGE decreased from 13.3% to 5.8%. Neuroimmunology/multiple sclerosis drugs represented >50% of the total payments despite being only 4.3% of claims.Conclusions Payments for neurologist-prescribed brand name, but not generic, drugs in Medicare Part D increased consistently and well above inflation from 2013 to 2017. Unless the overall trend stabilizes or is reversed or high cost-to-claim drugs are addressed, this trend will place an increasing burden on the neurologic Medicare budget.BNGE=brand name with generic equivalent; BNO=brand name only; GEN=generic